Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combination treatment, with BV administered...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2018
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855021/
https://ncbi.nlm.nih.gov/pubmed/29229594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-10-811224
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker